MedPath

Single Dose Monurol for Treatment of Acute Cystitis

Not Applicable
Completed
Conditions
Urinary Tract Infection
Interventions
Drug: TMP/SMX
Registration Number
NCT00976963
Lead Sponsor
University of Washington
Brief Summary

Urinary tract infecton (UTI) is a very common problem in young healthy women, afflicting approximately one-half of women by their late 20's. One of the most common antibiotics used to treat UTIs is Trimethoprim-Sulfamethoxazole (TMP-SMX), usually for total of three days. However, concerns about increased antibiotic resistance have led to increased interest in studying other antibiotics for UTI.

An alternative antibiotic which is also FDA approved for the treatment of UTIs is fosfomycin (Monurol). The effectiveness of fosfomycin in curing UTIs when given as a single dose is not well studied. The purpose of this research study is to determine what the cure rates are with a single dose of fosfomycin versus the more standard 3-day course of TMP-SMX.

Detailed Description

Procedures subjects will undergo once they have read and signed the consent are:

Questions about their medical and sexual history and current symptoms of UTI. They will be asked to provide a urine and peri-urethral sample and then are randomly assigned to one of the two treatment groups.They will be given a sheet to record symptoms at home. They will be asked to return to the clinic in 5-8 and 28-30 days after completing antibiotic therapy.Follow-up questions will be asked and urine and peri-urethral will be self collected at each visit.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
300
Inclusion Criteria
  • Non pregnant women in good health with symptoms of acute cystitis for less than 7 days
Exclusion Criteria
  • Pregnant, lactating, or not regularly contracepting
  • History of chronic conditions such as diabetes
  • Known anatomic abnormalities of the urinary tract
  • Use of prophylactic antibiotics
  • History of allergy or intolerance to any of the study drugs
  • Recent (> 2 weeks)exposure to oral or parenteral antimicrobial
  • History of UTI in previous 1 month

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TMP/SMXTMP/SMXSulfamethoxazole-Trimethoprim 800-160 MG Oral Tab; 800mg/160mg BID x 3 days
FosfomycinFosfomycin3g sachet single dose
Primary Outcome Measures
NameTimeMethod
Number of Participants Who Were Cured28-30 days post therapy

Cure as defined by no further treatment for subsequent or unresolved symptoms, by modified ITT approach.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Washington

🇺🇸

Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath